This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Proliferating cell nuclear antigen (PCNA)	<p><i>In vitro</i> studies suggest the triiodothyronine T3 derivative PCNA inhibitor T2AA could help treat cancer. <i>In vitro</i>, T2AA inhibited PCNA protein-protein interactions with an IC₅₀ of about 1 μM. In human cancer cell lines, T2AA inhibited proliferation and increased cisplatin-induced DNA damage compared with no treatment. Next steps could include optimizing T2AA to generate lead compounds with higher PCNA affinity.</p> <p>SciBX 5(12); doi:10.1038/scibx.2012.303 Published online March 22, 2012</p>	Patent and licensing status unavailable	<p>Punchihewa, C. <i>et al.</i> <i>J. Biol. Chem.</i>; published online March 1, 2012; doi:10.1074/jbc.M112.353201 Contact: Naoaki Fujii, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: naoaki.fujii@stjude.org</p>